ORCHESTRA BIOMED HOLDINGS INC.

NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)

最近更新时间: 46分钟之前

6.97

-0.15 (-2.11%)

前收盘价格 7.12
成交量 551,845
价格/销量 (P/S) 14.70
股市价格/股市净资产 (P/B) 57.25
52周波幅
3.46 (-50%) — 7.45 (6%)
营业利益率 (TTM) -2,179.84%
稀释每股收益 (EPS TTM) -1.77
季度收入增长率 (YOY) 40.00%
总债务/股东权益 (D/E MRQ) 97.55%
流动比率 (MRQ) 3.35
营业现金流 (OCF TTM) -54.06 M
杠杆自由现金流 (LFCF TTM) -28.16 M
资产报酬率 (ROA TTM) -60.70%
股东权益报酬率 (ROE TTM) -179.12%

AIStockmoo 评分

0.5
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
盈利能力弱。短期流动性充足。现金流为负。 参考
资本回报低于资本成本。资本回报下降。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年呈上升趋势。股价接近52周高点。 参考
股价与均线呈多头排列。主要均线走平。接近上升的均线。上涨日成交量较大。 参考
K线形态 参考 NA
高于中期趋势线。 参考
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻好坏参半或中性。 参考
多名内部人士近期净买入。 参考
机构在最新13F申报中净+5.72%的股份:61家增持,31家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化+11.0%,回补天数7天(FINRA)。 参考
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
股价高于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向上。短期动能上升。 参考
支撑与阻力没有明确信号。 参考
最终评分 0.53
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Orchestra BioMed Holdings, Inc. 混合的 看跌

相关股票

股票 市值 DY P/E(TTM) P/B
OBIO - - - 57.25
TRML 1 B - - 4.76
VRDN - - - 7.26
VRCA - - - 15.60
TECH - 0.44% - 5.28
ABEO - - - 1.10

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 21.81%
机构持股比例 49.62%
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
FAIN ERIC S 5.70 - 20,000 114,000
HOCHMAN DAVID P 5.70 - 5,000 28,500
PACITTI DAVID 5.70 - 20,000 114,000
TAYLOR ANDREW LAWRENCE 5.70 - 1,000 5,700
累积净数量 46,000
累积净值 ($) 262,200
累积平均购买 ($) 5.70
累积平均卖出 ($) -
名称 持有人 日期 类型 数量 价格 价值 ($)
TAYLOR ANDREW LAWRENCE 职员 09 Nov 2026 买 (+) 1,000 5.70 5,700
HOCHMAN DAVID P 职员 09 Nov 2026 买 (+) 5,000 5.70 28,500
PACITTI DAVID 董事 09 Nov 2026 买 (+) 20,000 5.70 114,000
FAIN ERIC S 董事 09 Nov 2026 买 (+) 20,000 5.70 114,000

机构

机构持股比例: 41.73%

持仓变动 机构数 股数
增持 61 5,034,559
减持 31 1,386,397
新建仓 27 1,437,879
清仓 11 569,836

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 2,732,484 7.0
15 Oct 2026 2,552,988 9.7
30 Sep 2026 2,547,249 7.0
15 Sep 2026 2,372,557 6.6
31 Aug 2026 2,460,669 5.8
14 Aug 2026 2,383,854 13.1

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

2 正面 3 负面 1 中性
日期 类型 细节
17 Nov 2026 Yahoo Finance Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
16 Nov 2026 Yahoo Finance Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
10 Nov 2026 Yahoo Finance Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
10 Nov 2026 Yahoo Finance Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
29 Oct 2026 Yahoo Finance Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels…
22 Oct 2026 Yahoo Finance Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq…
20 Oct 2026 Yahoo Finance OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .
01 Oct 2026 Yahoo Finance Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing…
21 Sep 2026 Yahoo Finance Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
16 Sep 2026 Yahoo Finance Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)…
15 Sep 2026 Yahoo Finance Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides…
02 Sep 2026 Yahoo Finance Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported…
27 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
20 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
显示更多

近期信号 K线形态与EMA交叉

▲ EMA看涨交叉 4个交易日前 · 11 Nov
短期 · EMA 7/20
7日EMA上穿20日EMA:短期动能转强。

技术形态 中期

趋势排列
斜率
入场位置
成交量
股价与均线呈多头排列。主要均线走平。接近上升的均线。上涨日成交量较大。
最近支撑: 6.36 – 6.62 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票